phenylalanine/悪性腫瘍

SEQUENCE LISTING A CRF copy of the Sequence Listing, titled 011808-0014-999_SeqListing.txt, which was saved on Apr. 22, 2008 and is 53 kbs in size is submitted herewith and is incorporated herein by reference in its entirety. FIELD OF THE INVENTION This invention relates to prokaryotic phenylalanine

SEQUENCE LISTING A CRF copy of the Sequence Listing, titled 11808-069-999_SeqListing.txt, which was saved on Apr. 8, 2009 and is 53,833 bytes in size is submitted herewith and is incorporated herein by reference in its entirety FIELD OF THE INVENTION This invention relates to prokaryotic

SEQUENCE LISTING A CRF copy of the Sequence Listing, titled 011808-0013-999_SeqListing.txt, which was saved on Apr. 22, 2008 and is 53 kbs in size is submitted herewith and is incorporated herein by reference in its entirety. FIELD OF THE INVENTION This invention relates to prokaryotic phenylalanine

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel conjugate of a phenylalanine derivative with an antitumor substance, a process for preparation thereof, and a pharmaceutical composition, in particular, an antitumor agent, containing it. More

BACKGROUND OF THE INVENTION The present invention relates to new phenylalanine derivatives and the use of the phenylalanine derivatives as medicines. It was reported that .alpha.4 integrins participate in diseases in which .alpha.4 integrin-depending adhesion process participates in the pathology,

BACKGROUND OF THE INVENTION The present invention relates to new phenylalanine derivatives and the use of the phenylalanine derivatives as medicines. It was reported that .alpha. 4 integrins participate in diseases in which .alpha. 4 integrin-depending adhesion process participates in the pathology,

BACKGROUND OF THE INVENTION The present invention relates to new phenylalanine derivatives and the use of the phenylalanine derivatives as medicines. The present invention also relates to the compounds usable as therapeutic agents or preventive agents for inflammatory diseases in which .alpha.4

BACKGROUND OF THE INVENTION The present invention relates to new phenylalanine derivatives and the use of the phenylalanine derivatives as medicines. The present invention also relates to the compounds usable as therapeutic agents or preventive agents for inflammatory diseases in which .alpha.4

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5

TECHNICAL FIELD OF THE INVENTION The present invention relates to novel phenylalanine derivatives, compositions, and a method of using these derivatives in inhibiting SH2 domain binding with a phosphoprotein. The present invention further provides precursors suitable for preparing the phenylalanine

CROSS REFERENCE TO RELATED APPLICATION This application is a 35 USC .sctn.371 National Phase Entry Application from PCT/EP2005/010143, filed Sep. 20, 2005, and designating the United States. The invention relates to improved and stable pharmaceutical formulations of phenylalanine derivatives and to

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a 35 U.S.C. .sctn.371 filing of PCT/EP2006/011367, filed Nov. 27, 2006. PCT/EP2006/011367 claims the benefit of European Patent Application No. 05025776.5, filed Nov. 25, 2005. The disclosures of the aforementioned applications are

FIELD OF THE INVENTION The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. BACKGROUND OF THE INVENTION Cancer treatments which target several pathways within cancer cells have been developed recently. However, some type of cancers exhibit different

BACKGROUND OF THE INVENTION Prostate cancer is the most common malignancy and the second leading cause of cancer death in men in the United States (Jemal A, et al., CA Cancer J Clin 2005; 55:10-30). Localized prostate cancer typically is treated with surgery or radiation, and recurrent disease can

The present invention provides a method for the treatment of malignant neoplasias comprising the step of administering an L-phenylalanine conjugated to a beta- or alpha-emitting isotope to a subject in the need thereof. Moreover, the invention provides a method for the monitoring of the progress of